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Summary
Background: Malignancy is generally considered a contra-
indication for cardiac transplantation, whereas secondary
malignancy has been described under chronic immunosup-
pression.
Patients and methods: We report here the frequency of
malignancy encountered among the 495 patients evaluated
at our cardiac transplant centre as well as the incidence and
the course of post-transplant malignancy among 129 con-
secutive patients who underwent cardiac transplantation,
with a subsequent minimum follow-up of 6 months.
Results: A total of 10 out of 495 patients (2%) evaluated
for heart transplantation presented with a history of previous
malignancy: 3 of them underwent transplantation (2 survive,
1 died) whereas in the remaining 7 patients neoplasia was
considered a contraindication for cardiac transplantation,
and all 7 died (4 cardiac, 3 tumor-related deaths). Post-trans-
plant malignancy was diagnosed in 10 of 129 patients (9%)
35 ± 15 months after transplantation (6 skin cancers, 1 lym-
phoproliferative disease, 3 solid tumors). No significant asso-
ciation was found between post-transplant malignancy and
primary prophylaxis with antithymocyte globulin (ATG) or
murine antihuman T-cell monoclonal antibodies (OKT3).
Conclusion: These results confirm that pre-transplant
malignancy is not an absolute contraindication for cardiac
transplantation and that post-transplant follow-up must
include careful monitoring of post-transplant malignancy.
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Introduction
The large increase in successful organ transplantation -
including cardiac - during the past 20 years is probably
due to the development of new immunosuppressive
drugs and the introduction of the triple regimen (cyclo-
sporine, azathioprine, prednisone) in the early 1980s
[1]. Early complications include acute allograft rejec-
tion, infection and surgical problems, whereas chronic
allograft rejection, cyclosporine nephrotoxicity, osteo-
porosis, accelerated allograft atherosclerosis and
malignancies occur in long-term follow-up [1-4]. An
increased incidence of neoplastic disorders has been
observed in patients undergoing immunosuppressive
therapy for organ transplantation [5-12].
Organ allograft transplantation is usually reserved
for patients with an end-stage organ disease without
evidence of other disease which would jeopardize the
result of transplantation. A pre-existing malignancy
may carry the risk of recurrent or de novo tumors due
to therapeutic immunosuppression and possible con-
sequent deficient immunomodulation. However, long-
term follow-up in carefully selected groups of patients
undergoing orthotopic heart transplantation with pre-
transplant neoplastic disease has been described
[13-16].
In this study we report the incidence and the out-
come of patients presenting with a history of previous
malignancy who were referred to our centre for evalua-
tion of cardiac transplantation, as well as the incidence
and the course of post-transplant malignancy in pa-
tients who underwent cardiac transplantation.
Patients and methods
The study includes a retrospective analysis of the incidence of malig-
nancy among 498 patients referred to the cardiac transplant centre
of the University Hospital of Zurich between September 1985 and
December 1992, as well as the incidence and the course of post-
transplant malignancy among the 150 patients undergoing cardiac
transplantation during the same period.
Pre-transplant malignancy
For all patients, pretransplant evaluation included along with the
usual exclusion criteria (active disease process, extensive degenera-
tive disease, vital organ dysfunction, poor compliance) an extensive
diagnostic scrutiny to exclude the subclinical presence of a neoplas-
tic disease by means of clinical, haematological, radiological routine
screening including abdominal and pelvic ultrasound. Gastrointes-
tinal endoscopic examination was performed in order to rule out
gastrointestinal neoplasia in 118 patients with unexplained anemia
and/or guaiacol-positive stool specimens; abdominal and chest CT
scans were performed in 31 patients to rule out the possibility of a
malignant retroperitoneal or mediastinal neoplastic process.
A history of malignancy was considered primarily a contraindi-
cation for cardiac transplantation. However, for selected cases
presenting a history of previous malignancy, a further extensive
1060
screening was performed to rule out the presence of any silent dis-
ease. In these cases, whether to accept or reject patients for cardiac
transplantation was decided on an individual basis by an inter-
disciplinary panel of specialists (including an oncologist). Particular
attention was paid to the natural history of the rumor, the patient's
life expectancy under the current optimal treatment of the tumor
with regard to the -histology, extent of the tumor (involvement of
adjacent lymph nodes or anatomical structures) and the tumor-free
interval at the time of evaluation for cardiac transplantation.
Post-transplant malignancy
Three patients with heart and lung transplantation were not includ-
ed. Two patients underwent a second orthotopic heart transplan-
tation; one of them died within a month of acute graft rejection, and
the second is alive 55 months after a second heart transplantation.
Eighteen patients had survival times of less than 6 months (most of
these died because of acute cell rejection, acute infection or im-
mediate post-operative problems). Autopsy was performed in 13 of
these 18 patients and no evidence of malignancy was found at
necropsy.
Thus, we observed 129 cardiac transplant recipients (118 males,
11 females) with a mean age of 47 ± 11 years (14 to 68 years) and a
minimal follow-up and survival time of 6 months. The patient with a
second transplantation is included and calculated as one. The mean
age of the patients at the time of heart transplantation was 44 ± 12
years, and the mean follow-up was 39 ± 23 months (6 to 99
months).
Immunosuppressive regimen
A total of 33 consecutive patients received early rejection prophy-
laxis with murine antihuman mature T-cell monoclonal antibodies
(OKT3, Cilag) during 14 days at a dose of 5 mg/day intravenously.
Ninety-six patients were treated with polyclonal anti-T-lymphocyte-
globulin (ATG, Fresenius) over 5 days at a dose of 4 mg/kg/day
intravenously. The mean follow-up of patients receiving OKT3 was
41 + 11 months and not statistically different from the follow-up of
patients receiving ATG (38 + 19 months) as early rejection prophy-
laxis.
The total amount administered per patient was 2.7 ± 0-9
g/patient for ATG and 67 ± 14 mg per patient for OKT3; 28 pa-
tients received a dosage of OKT3 <75 mg; the mean dosage of
OKT3 of the 5 patients receiving > 75 mg was 90 + 8 mg.
All patients received the basic immosuppressive regimen com-
monly used in our transplantation program which consists of oral
steroids (prednisone initially 1 mg/kg/day, tapering after the first
week to a mean level of 0.20 + 0.04 mg/kg/day), azathioprine
(1.45 + 0.60 mg/kg/day) and cyclosporine (5.2 + 1.5 mg/kg/day).
Episodes of cell rejection were defined according to the classifi-
cation of the International Society of Heart and Lung Transplanta-
tion (ISHT criteria) [17]. Episodes of mild cell rejection (ISHT 3A)
were treated with the intravenous application of 1 g methylpred-
nisolone/day for 3 days, episodes with ISHT 3B cell rejection were
treated with ATG (5 mg/kg/day) intravenously for 5 days and epi-
sodes of recurrent or more severe rejections with OKT3 (5 mg/day)
intravenously for 7 days.
Together with the usual monitoring for toxoplasma and cyto-
megalovirus, posttransplant follow-up included monitoring for the
Ebstein Barr Virus (EBV). IgM and IgG antibody levels for EBV
were monitored every week during the first month, every month
during the first 6 months after transplantation and at every sub-
sequent follow-up control (i.e., 2-3 times/year).
Results
Pre-transplant malignancy
Table 1 shows the 10 patients referred for evaluation
for cardiac transplantation presented with a history of
malignancy at the time of evaluation. All patients pre-
sented with an end-stage cardiac disease (NYHA m or
TV) due to dilated cardiomyopathy (4), end-stage coro-
nary artery disease (4), doxorubicin cardiomyopathy
(1) and cardiac sarcoma (1).
After evaluation, only 3 patients underwent heart
transplantation; in the remaining 7 it was considered
contraindicated because of associated neoplastic dis-
ease.
Patients with pre-transplant malignancy who underwent
cardiac transplantation
• Eight years after successful treatment of a Wilms'
tumor including whole abdomen radiation therapy,
chemotherapy with vincristine sulphate, dactinomycin,
cyclophosphamide and doxorubicin (860/m2) a 14-
year-old patient underwent orthotopic heart transplan-
tation because of an end-stage doxorubicin-induced
cardiomyopathy.
Eighty months after successful heart transplantation,
the now 22-year-old man is functionally fit and has no
signs of tumor relapse or de novo neoplasia.
• A 54-year-old man with an end-stage dilated cardio-
myopathy was referred for orthotopic heart transplan-
tation. A 4 x 2 x 2 cm polyp of the bulbus duodeni
detected during the work-up for transplant evaluation
was endoscopically resected. Histologica] diagnosis
revealed a duodenal carcinoid tumor, the immuno-
histochemical stains demonstrated cells producing
secretin, gastrin and somatostatin. The pre-transplant
surgical exploration of the abdomen showed one
micro-metastasis in the ligamentum hepato-duodenale.
The patient underwent heart transplantation after
eradication of the semimalignant tumor and confirma-
tion that there was no evidence of tumor relapse. Dur-
ing the 48 months since transplantation, there has been
no sign of rumor relapse at the regular endoscopic fol-
low-up nor by gastric hormone evaluation.
• A 31-year-old woman was referred for orthotopic
heart transplantation because of a local, echocardio-
graphically detected relapse of a cardiac synovial sar-
coma with central necrosis originating from the intra-
atrial septum of the right heart Chest X-ray, pre-trans-
plant chest CT scan and skeletal scintigraphy were
negative for extracardiac tumor involvement, and no
macroscopic metastasis was detectable at the time of
the operation.
Both atria were resected extensively and anastomo-
sis of the pulmonary artery was carried out in a stand-
ard end-to-end fashion as distal as possible. No chemo-
therapy or radiotherapy was administered. Two and a
1061
Table 1. Pretransplant malignancy.
1
2
3
4
5
6
7
8
9
10
Age
(years)
51
46
58
60
43
52
56
14
54
31
Sex
m
m
m
f
m
m
f
m
m
f
Cardiac
diagnosis
CMP
CAD
CMP
CMP
CAD
CAD
CAD
Doxorubicin
CMP
CMP
Cardiac
sarcoma
Severity
of cardiac
disease
(NYHA)
IV
ra-iv
rv
rv
ra-rv
IV
ra-rv
rv
ra
m
Cardiac
history
(months)*
30
15
28
36
12
28
24
48
18
3
Tumor diagnosis (tumor
treatment)
Colon adenocarcinoma
(surgery)
Lung epithelial cell
(surgery, RX)
Multiple myeloma (CX:
alkeran)
Breast adenocarcinoma
(surgery, tamoxifen)
Lung small-cell (CX)
Lung smooth epithelial
(surgery, RX)
Breast adenocarcinoma
(surgery, tamoxifen)
Wilms' renal tumor
(surgery, RX, CX)
Carcinoid duodenum
(surgery)
Cardiac sarcoma (sur-
gery, HTX)
Severity of
tumor dis-
ease (tumor
extension)
Cl (Duke's
type)
T2/N1/M0
stage IIIB
(Durie)
T2/N1/M0
T1/N1/M0
T1/N1/M0
T2/N1/M0
T2/N1/M1
T1/N1/M0
T2/N1/M0
Tumor
history
(months)1
13
9
43
15
9
14
12
96
6
3
Follow-up (months)1"
+ 15 (sudden cardiac
death)
+ 19 (extensive
tumor disease)
+ 12 (sudden cardiac
death
+ 12 (sudden cardiac
death)
+ 6 (sudden death
autopsy tumor infil-
tration)
+ 7 (diffuse meta)
+ 12 (sudden cardiac
death)
Alive, transplanted,
88 (NYHA I)
Alive, transplanted,
52 (NYHA I)
+ 3 (diffuse medias-
tinal infiltration)
Abbreviations: CMP - dilated cardiomyopathy; CAD - end stage coronary artery disease; NYHA - New York Heart Assocation classifi-
cation (I to FV); CX - chemotherapy; RX - radiotherapy; HTX - cardiac transplantation; + - death.
* Time interval between tumor diagnosis and the time of evaluation for cardiac transplantation.
b
 Months after the time of evaluation for cardiac transplantation.
half months after transplantation, the patient died of
tumor progression with extensive metastasis of the liver
and vertebral spine, and compression of the lungs by
pericardial lymph nodes. This patient was also included
in the group with pre-existing tumors although tumor
recurrence in this special case was coincidentally also
the main indication for heart transplantation.
Patients in whom pre-transplant malignancy was consid-
ered a contraindication for cardiac transplantation
(Table 1)
In 7 patients, cardiac transplantation was not per-
formed due to the initial presentation, extent and
tumor-free interval at the time of evaluation for trans-
plantation, with respect to the current prognosis of the
tumor. There were 1 small-cell and 2 epithelial cell
bronchial carcinomas, 2 breast adenocarcinomas, 1
adenocarcinoma of the colon and 1 multiple myeloma.
All 7 patients died within 6 to 19 months after trans-
plant evaluation: there were 4 cardiac deaths and 3
deaths associated with extensive progression of the
tumor.
However, tumor-free disease was documented in
only 1 patient at necropsy.
Post-transplant malignancy
Malignancies developed in 11 of 129 transplant reci-
pients (8.6%); their mean age at the time of transplan-
tation was 50 ± 5 years and 54 ± 4 years at the time of
diagnosis of malignant disease. The mean elapsed time
before the appearance of malignancy after cardiac
transplantation was 35 ± 15 months. The observation
period lasted 24 ± 11 months (13 to 44 months) after
tumor diagnosis.
For the 11 patients with posttransplant malignancy
the mean dosage of cyclosporine, azathioprine and
steroids were 5.1 + 0.8 mg/kg/day, 1.43 + 0.5 mg/kg/
day and 0.20 + 0.05 mg/kg/day and were not statisti-
cally different from the corresponding levels in the 118
patients without evidence of posttransplant malig-
nancy.
Follow-up in patients receiving ATG was 3 8 + 1 9
months versus 4 1 + 1 1 months in patients receiving
OKT3 as early rejection prophylaxis. The number of
episodes of mild and moderate cell rejection (ISHT >
3a) was 3.2 + 1.7 per patient for the 11 patients with
posttransplant malignancy and 3.1 + 1.8 per patient in
the group of the 118 patients without evidence of
malignancy.
• The most frequent tumors were skin (n = 6, 54%):
squamous cell carcinoma (3), basal cell carcinoma (2)
and malignant melanoma (1), and the mean time to
appearance after transplantation was 19 ± 14 months.
No local relapse or metastatic tumor progression had
occurred after local excision of the tumors at a mean
observation time of 34 ± 15 months (14-65 months).
Immunosuppression therapy remained the same after
total excision of the tumors.
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Table 2. Post-transplant malignancy.
Tumour diagnosis Tune of Early
tumor rejection
diagnosis prophylaxis
(months
after HTX)
Tumor treatment Survival
(months
after
tumor
diag-
nosis)
Squamous cell car- 57/42/9
cinoma (3 patients)
ATG/ATG/ Excision
ATG
Basal cell carci-
noma (2 patients)
Malignant mela-
noma (1 patient)
Kaposi's sar-
coma (1 patient)
Lymphoprolifera-
tive disorder
(1 patient)
Metastatic adeno-
carcinoma (stom-
ach)
Metastatic adeno-
carcinoma (colon)
Breast cancer
(T2 NO MO)
51/38
50
35
39
27
24
13
ATG/OKT3 Excision
ATG
OKT3
52V22V
19"
40V211
Excision, reduced 49"
immunosuppression
Reduced immuno- 32"
suppression, chlor-
ambucilum
OKT3 Cessation of im- l'/2'
munosuppression,
chemotherapy
OKT 3 Symptomatic 3b
therapy
ATG No therapy 1b
ATG Radical mastec- 351
tomy
* Alive after orthotopic heart transplantation (HTX).
b
 Dead.
• There was one case of Kaposi sarcoma occurring 35
months after transplantation and presenting with multi-
ple skin lesions and mucosal involvement of the stom-
ach confirmed at endoscopic and histological exam-
ination. Following a drastic reduction in immunosup-
pression (cessation of azathioprine and reduction in
cyclosporine A), there was only partial resolution of the
Kaposi sarcoma; complete recovery occurred only after
two courses of chlorambucil (5 mg).
• Lymphoproliferative disease was diagnosed in one
patient who received OKT3 at a dosage of 95 mg 5
months after transplantation and who presented with
weight lost, fever of unknown origin and pancytopenia.
There was no evidence of recent or acute EBV infec-
tion (normal IgM and IgG antibody levels). On bone
marrow examination a diffuse lymphoproliferative
infiltration corresponding to lymphatic leukaemia or
lymphoblastic lymphoma was present An exact diag-
nosis of the immunohistological identified T-cells could
not be established. Despite cessation of immuno-
suppressive therapy and chemotherapy with bleomycin,
vincristine sulphate, cyclophosphamide, cisplatin and
prednisone, the lymphoblastic infiltration of bone mar-
row persisted.
The patient died one and a half months after tumor
diagnosis of a fulminant septicemia induced by agranu-
locytosis. At necropsy, a persistent bone marrow
aplasia without T-cell proliferation, chronic pneumonia
and necrotic bronchiolitis caused by an infiltrative
aspergillosis were found.
No secondary lymphomas were found in any other
long-term surviving patients, particularly in those re-
ceiving OKT3 as primary prophylaxis. Secondary lym-
phomas were not found at autopsy in 13 of the 18
patients who died of rejection or infection during the
early follow-up and who were autopsied.
Asymtomatic increase of IgM and IgG antibody lev-
els for EBV occurred in only one patient receiving
OKT3 as a primary prophylaxis at 4 and 5 months after
transplantation, respectively. There was no evidence of
neoplasia or lymphoma in this patient at the three-year
follow-up.
• There was one breast adenocarcinoma (T2, NO, MO)
occurring 13 months after cardiac transplantation with
tumor-free follow-up of 27 months after radical resec-
tion and treatment with tamoxifen. Two patients devel-
oped gastrointestinal adenocarcinoma at 24 and 27
months after transplantation, both of them with liver
metastasis at tumor presentation and a consequent un-
favourable course.
Discussion
Our results support the opinion that a history of malig-
nancy is not an absolute contraindication for cardiac
transplantation [13-17]. Careful selection of the pa-
tients is, however, required with respect to the form of
presentation, histology, extent of the tumor, the tumor-
free interval at the time of transplant evaluation and the
life expectancy under the current optimal treatment of
the tumor. Our data also underline the dilemma of this
decision and indicate that in patients ultimately not
selected for heart transplantation because of a previous
history of malignancy more than half died within one
and a half years of cardiac causes. However, the grow-
ing problem of the shortage of organs due to the imbal-
ance between the increasing number of candidates for
cardiac transplantation and the limited number of
potential donors with the consequent increasing num-
ber of patients dying on the waiting lists suggest that
patients with poor tumor-related long-term prognoses
should still not be transplanted. The emerging role of
the artificial heart in patients with terminal heart dis-
eases remains an experimental procedure in humans
but in future could change the perspective of this prob-
lem.
In our series, there was only one patient presenting
with an history of doxorubicin-induced cardiomyo-
pathy with an excellent cardiac and oncological long-
term result. The increasing numbers of patients receiv-
ing more aggressive oncological regimens (i.e., those
undergoing autologous bone transplantation, for breast
cancer or non-Hodgkin's lymphoma) will probably give
rise in the future to the problem of cardiac transplan-
tation for selected cases with toxicity-induced cardio-
myopathy [18].
Our findings on the incidence and course of post-
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transplant malignancy confirm the data of large series
and registries indicating malignant skin rumors as the
most frequent secondary tumor, with an overall good
prognosis [6-12]. In our case of Kaposi sarcoma, a
drastic reduction in immunosuppression was not suffi-
cient to obtain a complete resolution and only the addi-
tion of chlorambucil resulted in achievement of a
definite regression of the Kaposi. One interesting find-
ing in our follow-up study, which included a consider-
able number of patients receiving OKT3 as early rejec-
tion prophylaxis, was the low incidence of lymphoma
[19, 20]. This incidence of secondary lymphomas may
be explained by the low incidence of EBV infection
(< 1%) in our patients and by the fact that only a minor-
ity of patients received a dosage greater than 75 mg of
OKT3. A high prevalence of lymphomas has been re-
ported in patients receiving high dosages of OKT3 [19,
20]. The small number of patients in our series receiv-
ing more than 75 mg of OKT3 do not allow a statistical
comparison between patients receiving different dos-
ages of OKT3.
Although our findings from a single heart transplant
center are based on a retrospective analysis and on a
limited number of patients and observation time, and
therefore probably underestimate the incidence of
post-transplant malignancy, they clearly indicate the
importance of pre- and post-transplant tumor screen-
ing in patients undergoing evaluation and for patients
selected for cardiac transplantation.
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